Volume 26, Number 7—July 2020
Research Letter
Zika Virus Detection with 2013 Serosurvey, Mombasa, Kenya
Table
Participant no. | Age, y | CDC ZIKV MAC ELISA P/N ratio (IgM) | ZIKV PRNT90 titer | DENV PRNT90 titer | Participant type | Final interpretation of case |
---|---|---|---|---|---|---|
2 | 63 | 3.56 | 1:20 | <1:20 | Serosurvey | ZIKV |
3 | 50 | 10.00 | >1:320 | <1:20 | Serosurvey | ZIKV |
5 | 70 | 3.17 | 1:20 | <1:20 | Serosurvey | ZIKV |
10 | NA | 3.51 | 1:20 | <1:20 | Hospital | ZIKV |
31 | 51 | 5.50 | >1:320 | 1:20 | Serosurvey | ZIKV |
4 | 45 | 3.26 | <1:20 | 1:20 | Serosurvey | DENV |
7 | 36 | 8.65 | 1:20 | 1:320 | Serosurvey | DENV |
20 | 58 | 13.18 | 1:20 | 1:320 | Serosurvey | DENV |
25 | 45 | 3.70 | 1:20 | >1:320 | Serosurvey | DENV |
26 | 27 | 5.00 | 1:80 | >1:320 | Serosurvey | DENV |
27 | 42 | 3.20 | 1:80 | 1:320 | Serosurvey | DENV |
33 | 30 | 10.70 | 1:20 | 1:80 | Serosurvey | DENV |
1 | 32 | 4.49 | 1:20 | 1:20 | Serosurvey | Cross-reactive |
9 | 27 | 3.82 | 1:20 | 1:20 | Serosurvey | Cross-reactive |
30 | 58 | 3.20 | >1:320 | >1:320 | Serosurvey | Cross-reactive |
6 | 41 | 16.35 | 1:20 | ND | Serosurvey | Inconclusive |
*CDC, Centers for Disease Control and Prevention; DENV, dengue virus; MAC, IgM antibody capture; NA, not available; ND, not done due to insufficient specimen; PRNT90, plaque reduction neutralization test 90%; ZIKV, Zika virus.
Page created: March 18, 2020
Page updated: June 18, 2020
Page reviewed: June 18, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.